Washington State’s program is the first, but other states are expected to try allowing pharmacists to prescribe the pills to ...

Truist analyst David MacDonald lowered the firm’s price target on CVS Health (CVS) to $60 from $67 and keeps a Buy rating on ...

Zydus Pharmaceuticals USA Inc President & CEO Punit Patel said the relationship is a strong validation of Zydus' strategic investments in the new drug applications portfolio.

Zydus Lifesciences announces CVS Caremark agreement and FDA priority review for diabetes and Menkes disease treatments.

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

Zydus Lifesciences (including its subsidiaries/affiliates, hereafter referred to as 'Zydus'), a global innovation driven healthcare company announced that it has entered into an agreement with CVS ...

Zydus Lifesciences reacted sharply to the development in Tuesday's trade with the counter rising 5.23 percent to an intraday high of Rs 1,011.75 per share on the NSE.

A customer who was in a CVS parking lot in Wyandotte noticed the baby alone, strapped in the back seat of a booster seat.

It is a scary situation no baby should ever be in, being left alone in a car with no parents or guardians around.

Shares of CVS Health Corp. CVS inched 0.11% higher to $45.82 Monday, on what proved to be an all-around mixed trading session ...

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by ...